Glenmark Pharma Gets U.S. FDA Approval for Fluticasone Nasal Spray

Glenmark Pharmaceuticals has received U.S. FDA approval for Fluticasone Propionate Nasal Spray 0.05 mg/spray, expanding its respiratory product portfolio in the U.S. market. Key Highlights • The approved product is bioequivalent and therapeutically equivalent to Flonase® Nasal Spray. • Glenmark Pharmaceuticals Inc., USA will distribute the product in the U.S. • Flonase® recorded market sales of approximately $295.2 million for the 12 months ended June 2026. • The approval adds another product to Glenmark’s respiratory portfolio in the U.S. Why It Matters The U.S. FDA approval provides Glenmark with an opportunity to participate in a product category with an established market. The approved Fluticasone Propionate Nasal Spray is equivalent to Flonase® Nasal Spray, while Glenmark Pharmaceuticals Inc., USA will handle distribution. With Flonase® generating approximately $295.2 million in market sales over the 12 months ended June 2026, the approval highlights the commercial opportunity associated with the product. The approval further expands Glenmark’s respiratory portfolio in the U.S. and adds another product to its presence in the market.